Compare DMLP & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DMLP | YDES |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | DMLP | YDES |
|---|---|---|
| Price | $22.21 | $12.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 224.2K | 89.0K |
| Earning Date | 11-06-2025 | 09-30-2025 |
| Dividend Yield | ★ 14.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $143,803,000.00 | $510,360.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | N/A | ★ 45.76 |
| 52 Week Low | $20.85 | $5.30 |
| 52 Week High | $34.88 | $31.00 |
| Indicator | DMLP | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | N/A |
| Support Level | $21.39 | N/A |
| Resistance Level | $22.60 | N/A |
| Average True Range (ATR) | 0.75 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 39.36 | 0.00 |
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.